A	0	1	O
novel	2	7	O
role	8	12	O
of	13	15	O
thrombospondin	16	30	B-Gene_or_gene_product
-	30	31	I-Gene_or_gene_product
1	31	32	I-Gene_or_gene_product
in	33	35	O
cervical	36	44	B-Multi-tissue_structure
carcinogenesis	45	59	O
:	59	60	O
inhibit	61	68	O
stroma	69	75	B-Tissue
reaction	76	84	O
by	85	87	O
inhibiting	88	98	O
activated	99	108	O
fibroblasts	109	120	B-Cell
from	121	125	O
invading	126	134	O
cancer	135	141	B-Pathological_formation
.	141	142	O

Thrombospondin	144	158	B-Gene_or_gene_product
(	159	160	I-Gene_or_gene_product
TSP	160	163	I-Gene_or_gene_product
)	163	164	I-Gene_or_gene_product
-	164	165	I-Gene_or_gene_product
1	165	166	I-Gene_or_gene_product
,	166	167	O
a	168	169	O
potent	170	176	O
angiogenesis	177	189	O
inhibitor	190	199	O
,	199	200	O
has	201	204	O
been	205	209	O
shown	210	215	O
to	216	218	O
exert	219	224	O
different	225	234	O
biological	235	245	O
functions	246	255	O
on	256	258	O
various	259	266	O
cell	267	271	B-Cell
types	272	277	O
.	277	278	O

Here	279	283	O
,	283	284	O
we	285	287	O
investigate	288	299	O
the	300	303	O
role	304	308	O
of	309	311	O
TSP	312	315	B-Gene_or_gene_product
-	315	316	I-Gene_or_gene_product
1	316	317	I-Gene_or_gene_product
in	318	320	O
tumor	321	326	B-Pathological_formation
-	326	327	O
stroma	327	333	B-Tissue
reaction	334	342	O
,	342	343	O
which	344	349	O
is	350	352	O
mainly	353	359	O
characterized	360	373	O
by	374	376	O
fibroblast	377	387	B-Cell
activation	388	398	O
to	399	401	O
create	402	408	O
a	409	410	O
permissive	411	421	O
microenvironment	422	438	O
for	439	442	O
tumor	443	448	B-Pathological_formation
progression	449	460	O
.	460	461	O

Immunohistochemistry	462	482	O
examinations	483	495	O
in	496	498	O
the	499	502	O
human	503	508	B-Organism
surgical	509	517	O
specimens	518	527	O
have	528	532	O
shown	533	538	O
that	539	543	O
a	544	545	O
downregulation	546	560	O
of	561	563	O
TSP	564	567	B-Gene_or_gene_product
-	567	568	I-Gene_or_gene_product
1	568	569	I-Gene_or_gene_product
during	570	576	O
the	577	580	O
progression	581	592	O
of	593	595	O
cervical	596	604	B-Multi-tissue_structure
carcinogenesis	605	619	O
was	620	623	O
accompanied	624	635	O
by	636	638	O
an	639	641	O
emergence	642	651	O
in	652	654	O
the	655	658	O
upregulation	659	671	O
of	672	674	O
stroma	675	681	B-Gene_or_gene_product
markers	682	689	I-Gene_or_gene_product
,	689	690	O
alpha	691	696	B-Gene_or_gene_product
-	696	697	I-Gene_or_gene_product
smooth	697	703	I-Gene_or_gene_product
muscle	704	710	I-Gene_or_gene_product
actin	711	716	I-Gene_or_gene_product
(	717	718	O
alpha	718	723	B-Gene_or_gene_product
-	723	724	I-Gene_or_gene_product
SMA	724	727	I-Gene_or_gene_product
)	727	728	O
and	729	732	O
desmin	733	739	B-Gene_or_gene_product
.	739	740	O

Transfection	741	753	O
of	754	756	O
SiHa	757	761	B-Cell
cervical	762	770	I-Cell
cancer	771	777	I-Cell
cells	778	783	I-Cell
with	784	788	O
a	789	790	O
plasmid	791	798	O
expressing	799	809	O
the	810	813	O
TSP	814	817	B-Gene_or_gene_product
-	817	818	I-Gene_or_gene_product
1	818	819	I-Gene_or_gene_product
protein	820	827	O
exhibited	828	837	O
antiangiogenic	838	852	O
activity	853	861	O
in	862	864	O
vitro	865	870	O
and	871	874	O
resulted	875	883	O
in	884	886	O
reduced	887	894	O
tumor	895	900	B-Pathological_formation
growth	901	907	O
in	908	910	O
severe	911	917	O
combined	918	926	O
immunodeficiency	927	943	O
(	944	945	O
SCID	945	949	O
)	949	950	O
mice	951	955	B-Organism
,	955	956	O
which	957	962	O
was	963	966	O
accompanied	967	978	O
by	979	981	O
a	982	983	O
decrease	984	992	O
in	993	995	O
tumor	996	1001	B-Pathological_formation
vascularization	1002	1017	O
and	1018	1021	O
lower	1022	1027	O
expressions	1028	1039	O
of	1040	1042	O
alpha	1043	1048	B-Gene_or_gene_product
-	1048	1049	I-Gene_or_gene_product
SMA	1049	1052	I-Gene_or_gene_product
and	1053	1056	O
desmin	1057	1063	B-Gene_or_gene_product
than	1064	1068	O
those	1069	1074	O
in	1075	1077	O
the	1078	1081	O
vector	1082	1088	O
controls	1089	1097	O
.	1097	1098	O

Transfection	1099	1111	O
with	1112	1116	O
TSP	1117	1120	B-Gene_or_gene_product
-	1120	1121	I-Gene_or_gene_product
1	1121	1122	I-Gene_or_gene_product
and	1123	1126	O
purified	1127	1135	O
TSP	1136	1139	B-Gene_or_gene_product
-	1139	1140	I-Gene_or_gene_product
1	1140	1141	I-Gene_or_gene_product
added	1142	1147	O
to	1148	1150	O
NIH3T3	1151	1157	B-Cell
cells	1158	1163	I-Cell
did	1164	1167	O
not	1168	1171	O
alter	1172	1177	O
the	1178	1181	O
protein	1182	1189	O
levels	1190	1196	O
of	1197	1199	O
alpha	1200	1205	B-Gene_or_gene_product
-	1205	1206	I-Gene_or_gene_product
SMA	1206	1209	I-Gene_or_gene_product
and	1210	1213	O
desmin	1214	1220	B-Gene_or_gene_product
but	1221	1224	O
significantly	1225	1238	O
inhibited	1239	1248	O
matrix	1249	1255	B-Gene_or_gene_product
metalloprotease	1256	1271	I-Gene_or_gene_product
-	1271	1272	I-Gene_or_gene_product
2	1272	1273	I-Gene_or_gene_product
activity	1274	1282	O
.	1282	1283	O

Transforming	1284	1296	B-Gene_or_gene_product
growth	1297	1303	I-Gene_or_gene_product
factor	1304	1310	I-Gene_or_gene_product
-	1310	1311	I-Gene_or_gene_product
beta	1311	1315	I-Gene_or_gene_product
(	1316	1317	O
TGF	1317	1320	B-Gene_or_gene_product
-	1320	1321	I-Gene_or_gene_product
beta	1321	1325	I-Gene_or_gene_product
)	1325	1326	O
,	1326	1327	O
a	1328	1329	O
major	1330	1335	O
factor	1336	1342	O
in	1343	1345	O
the	1346	1349	O
activation	1350	1360	O
of	1361	1363	O
fibroblasts	1364	1375	B-Cell
,	1375	1376	O
increased	1377	1386	O
alpha	1387	1392	B-Gene_or_gene_product
-	1392	1393	I-Gene_or_gene_product
SMA	1393	1396	I-Gene_or_gene_product
and	1397	1400	O
desmin	1401	1407	B-Gene_or_gene_product
expression	1408	1418	O
and	1419	1422	O
the	1423	1426	O
ability	1427	1434	O
of	1435	1437	O
cell	1438	1442	B-Cell
migration	1443	1452	O
and	1453	1456	O
invasion	1457	1465	O
in	1466	1468	O
NIH3T3	1469	1475	B-Cell
cells	1476	1481	I-Cell
.	1481	1482	O

The	1483	1486	O
increased	1487	1496	O
migration	1497	1506	O
ability	1507	1514	O
and	1515	1518	O
the	1519	1522	O
invasive	1523	1531	O
ability	1532	1539	O
into	1540	1544	O
tumor	1545	1550	B-Pathological_formation
cluster	1551	1558	O
of	1559	1561	O
TGF	1562	1565	B-Gene_or_gene_product
-	1565	1566	I-Gene_or_gene_product
beta	1566	1570	I-Gene_or_gene_product
-	1570	1571	O
treated	1571	1578	O
NIH3T3	1579	1585	B-Cell
cells	1586	1591	I-Cell
were	1592	1596	O
dose	1597	1601	O
dependently	1602	1613	O
inhibited	1614	1623	O
by	1624	1626	O
TSP	1627	1630	B-Gene_or_gene_product
-	1630	1631	I-Gene_or_gene_product
1	1631	1632	I-Gene_or_gene_product
.	1632	1633	O

In	1634	1636	O
contrast	1637	1645	O
,	1645	1646	O
ectopic	1647	1654	O
TSP	1655	1658	B-Gene_or_gene_product
-	1658	1659	I-Gene_or_gene_product
1	1659	1660	I-Gene_or_gene_product
expression	1661	1671	O
in	1672	1674	O
SiHa	1675	1679	B-Cell
cells	1680	1685	I-Cell
has	1686	1689	O
little	1690	1696	O
effect	1697	1703	O
on	1704	1706	O
the	1707	1710	O
invasive	1711	1719	O
ability	1720	1727	O
of	1728	1730	O
the	1731	1734	O
NIH3T3	1735	1741	B-Cell
cells	1742	1747	I-Cell
.	1747	1748	O

Together	1749	1757	O
,	1757	1758	O
our	1759	1762	O
findings	1763	1771	O
demonstrate	1772	1783	O
a	1784	1785	O
novel	1786	1791	O
role	1792	1796	O
of	1797	1799	O
TSP	1800	1803	B-Gene_or_gene_product
-	1803	1804	I-Gene_or_gene_product
1	1804	1805	I-Gene_or_gene_product
to	1806	1808	O
inhibit	1809	1816	O
tumor	1817	1822	B-Pathological_formation
-	1822	1823	O
stroma	1823	1829	B-Tissue
reaction	1830	1838	O
that	1839	1843	O
could	1844	1849	O
be	1850	1852	O
attributed	1853	1863	O
to	1864	1866	O
the	1867	1870	O
blockage	1871	1879	O
of	1880	1882	O
activated	1883	1892	O
fibroblasts	1893	1904	B-Cell
from	1905	1909	O
invading	1910	1918	O
cancer	1919	1925	B-Cell
cells	1926	1931	I-Cell
.	1931	1932	O

